Also known as: FPF-1070 · Cerebrolysate · Cerebrolysin injection
Cerebrolysin is a standardised mixture of neuropeptides and amino acids derived from porcine brain tissue that mimics the effects of endogenous neurotrophic factors. It promotes neuroplasticity, protects against neurodegeneration, and improves cognitive function in stroke recovery and dementia research.
Cerebrolysin is a standardised injectable preparation containing approximately 25% low-molecular-weight peptides and 75% free amino acids, derived from purified porcine brain proteins. The active peptide fraction penetrates the blood-brain barrier and exerts neurotrophic effects that mimic BDNF, NGF, and CNTF.
It has regulatory approval in multiple countries for stroke, traumatic brain injury, and dementia. A 2020 Cochrane review found significant cognitive improvements in vascular dementia patients across 149 trials.
Cerebrolysin activates TrkB and TrkA receptors (BDNF and NGF receptors), stimulating MAPK/ERK and PI3K/Akt neuroprotective cascades. It increases BDNF synthesis, promotes dendritic branching, inhibits caspase-mediated apoptosis, reduces amyloid precursor protein processing, and downregulates tau hyperphosphorylation. It also modulates NMDA receptor activity, reducing glutamate excitotoxicity.
Cerebrolysin is approved in 50+ countries but not FDA-approved in the US. Available as pre-made ampoules (1 mL, 2 mL, 5 mL, 10 mL concentrations). Generally well-tolerated; minor injection-site reactions most common. Allergic reactions rare but possible given porcine origin — test with small dose first. IV administration preferred for maximum CNS effect.
Course-based administration is standard. Cognitive enhancement protocols use 10-day courses repeated 3–4 times yearly. Neurological recovery protocols use 20-day courses with 4–8 week gaps between. Effects often continue to improve for weeks after course completion due to neuroplasticity mechanisms.
Administered by IV infusion or IM injection. Typical protocol: 5–30 mL daily for 10–20 day courses. IV infusion preferred for neurological indications. Approved in 50+ countries; not FDA-approved in the US.
Ask anything about Cerebrolysin — mechanisms, dosing protocols, interactions, or research comparisons.
Selank is a synthetic heptapeptide developed at the Russian Institute of Molecular Genetics, derived from the endogenous…
Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) 4–10 fragment, developed at the Insti…
Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide first isolated from rabbit thalamus in 1977 by Schoenen…
Dihexa is a potent peptidomimetic derived from angiotensin IV that acts as a superagonist of the HGF/MET signaling syste…